Australian Clinical Society of Allergy and Immunology has just informed Allergists that Mylan (who distrubitue Epipens) has announced a shortage of EpiPen® 300mcg adrenaline (epinephrine) autoinjectors. Supply of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors is unaffected.
- Stock is expected to be available in pharmacies from mid-February 2018.
- A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need. Mylan has requested patients requiring an EpiPen® 300mcg autoinjector contact their local pharmacy. Pharmacies can then contact Mylan by phoning 1800 274 276 or by emailing email@example.com to obtain instructions on how to access an emergency supply.
- Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves in mid-February 2018.
- Patients and/or carers who require support should contact the national patient support organisations, Allergy & Anaphylaxis Australia via email firstname.lastname@example.org or by calling 1300 728000 or Allergy New Zealand www.allergy.org.nz
Use of expired adrenaline (epinephrine) autoinjectors
- It is important to note that a device expiring in February 2018 does not expire until the end of that month, not the start of that month.
- Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency.
- Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised.